Literature DB >> 22020430

Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?

O Tamburrini1, A Balducci.   

Abstract

We review the current approach to using gadoliniumbased contrast agents taking into account data published in the literature and US Food and Drug Administration and European Medicines Evaluation Agency (EMEA) guidelines.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22020430     DOI： 10.1007/s11547-011-0737-y

Source DB:  PubMed          Journal:  Radiol Med        ISSN： 0033-8362            Impact factor:   3.469


  13 in total

1.  Fresh blood imaging of the peripheral vasculature: an emerging unenhanced MR technique.

Authors:  Edward T D Hoey; Arul Ganeshan; Rakesh Puni; John Henderson; Paul M Crowe
Journal:  AJR Am J Roentgenol       Date:  2010-12       Impact factor: 3.959

2.  Off-label use of intravascular iodinated organic and MR contrast media.

Authors:  O Tamburrini; I Aprile; C Falcone; D Console; A Rotundo; A Rotondo
Journal:  Radiol Med       Date:  2010-10-27       Impact factor: 3.469

3.  Which study when? Iodinated contrast-enhanced CT versus gadolinium-enhanced MR imaging.

Authors:  Robert A Halvorsen
Journal:  Radiology       Date:  2008-10       Impact factor: 11.105

4.  Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media.

Authors:  O Rees; S K Agarwal
Journal:  Clin Radiol       Date:  2010-06-11       Impact factor: 2.350

5.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

6.  Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008.

Authors:  Kyung-Ho Kim; Jennifer R Fonda; Elizabeth V Lawler; David Gagnon; James S Kaufman
Journal:  Am J Kidney Dis       Date:  2010-06-26       Impact factor: 8.860

7.  Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.

Authors:  Michael Edward; Jean A Quinn; A David Burden; Ben B Newton; Alan G Jardine
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

8.  Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.

Authors:  Ersan Altun; Diego R Martin; Rebecca Wertman; Aida Lugo-Somolinos; Edwin R Fuller; Richard C Semelka
Journal:  Radiology       Date:  2009-09-29       Impact factor: 11.105

9.  Exposure to low-dose ionizing radiation from medical imaging procedures.

Authors:  Reza Fazel; Harlan M Krumholz; Yongfei Wang; Joseph S Ross; Jersey Chen; Henry H Ting; Nilay D Shah; Khurram Nasir; Andrew J Einstein; Brahmajee K Nallamothu
Journal:  N Engl J Med       Date:  2009-08-27       Impact factor: 91.245

10.  Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis.

Authors:  P Marckmann; L Skov; K Rossen; H S Thomsen
Journal:  Clin Nephrol       Date:  2008-03       Impact factor: 0.975
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.